针对复发性静脉静脉复缩 (AI-ISR) 的抗炎疗法:为前性,随机化,开放标签,多中心临床试验的研究方案
Miao Yu1, Yu Jiang1, Zhifeng Song1
1State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
BMJ open
|October 27, 2025
概括
这项研究调查了胆固醇或普得尼松是否可以降低冠状动脉干预后的静脉静脉阻塞. 该试验将这些抗炎药物与标准治疗进行比较,以防止重复手术和心血管事件.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 复发性静脉静脉复缩 (RISR) 是皮肤冠状动脉干预 (PCI) 的一个显著并发症,导致重复的血管化和增加的死亡率.
- 免疫介导的炎症是RISR发展的关键因素.
- 目前对RISR的治疗选择有限,需要新的治疗策略.
研究的目的:
- 为了评估低剂量胆固醇和普得尼松的临床疗效和安全性,以减少静脉静脉复发 (ISR) 的复发.
- 评估这些抗炎策略对主要心血管和脑血管不良事件的影响.
- 为了比较科尔奇辛和普得尼松与RISR患者的标准医疗疗疗法的有效性.
主要方法:
- 一个多中心,前性,随机化,开放标签的受控试验,涉及252名RISR患者.
- 患者被分配接受标准的医疗治疗,低剂量胆固醇 (0.5毫克/天) 或普雷尼松 (0.5毫克/公斤/天,在12个月内逐渐缩小).
- 主要终点是PCI后12个月内血管学证实的ISR,次要终点包括主要不良心血管事件和再血管化率.
主要成果:
- 关于主要结果的数据尚未提供,因为这是一个前性试验.
- 主要终点是评估12个月后血管学确认的支架内静止症.
- 二级终点侧重于心血管死亡,心肌梗塞,中风和重血管事件.
结论:
- 这项研究旨在提供关于抗炎药物在控制RISR中的有效性的证据.
- 这些研究结果将为临床实践提供有关使用科尔奇辛和普得尼松来预防ISR的信息.
- 该试验将有助于了解炎症在静止症中的作用及其治疗调节.
相关概念视频
Peripheral Artery Disease III: Interprofessional Care
236
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
236
Atherosclerosis III: Management
312
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
312
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
452
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
452
Coronary Artery Disease V: Interprofessional Care
210
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
210
Acute Coronary Syndrome III: Diagnostic Studies
207
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
207


